Huinuo Biopharmaceutical Technology

Huinor Biopharma (also known as Phaeno Therapeutics) is a clinical-stage biopharmaceutical company founded in 2018, specializing in the discovery and development of innovative anti-infective therapies. Headquartered in Hangzhou with R&D operations in Shanghai, the company focuses on high-unmet-need areas such as viral infections (HSV, HCMV, HBV, Influenza) and drug-resistant bacterial infections. Its lead candidate, HN0037, is a small molecule helicase-primase inhibitor currently in Phase 2 clinical trials for the treatment of recurrent genital herpes and herpes labialis. Another key asset, HN0141, is a terminase inhibitor for human cytomegalovirus (HCMV) in Phase 1 development. The company is led by industry veterans from GSK and Ferring and is backed by prominent investors including Qiming Venture Partners and Joincare.